incomplete, and such lesions could perhaps have been overlooked. Our patient had no nail involvement. Professor M W Greaves: This patient had peripheral oedema which appeared to be of the lymphatic type. In view of the evidence that about one-fifth of patients with primary lymphoedema have a protein-losing enteropathy (Eustace et al., 1975, British Medical Journal iv, 737) , I wonder if you have carried out studies of faecal loss of plasma proteins. Dr Klaber: Most patients with anal bum inaemia do not have oedema; indeed, it has only been recorded once before. The defect is one of albumin synthesis and therefore the measured radioiodinated albumin faecal loss was very low.
Rumanian cutaneous leishmaniasis 1 Valerie Neild MB MRCP West Middlesex Hospital, Isleworth, Middlesex
In January 1977 Mrs J J, aged 53 years, presented with swelling and erythema of the left cheek, spreading from a vesicular crusted area above her upper lip ( Figure I ). The previous summer she had had a holiday in Rumania on the Black-Sea coast and two months later she first noticed a spot on her upper lip; there had been gradual extension of the area since. Skin biopsy showed a florid noncaseating tuberculoid granuloma (specific stains for acidfast bacilli, fungi, and leishmania were negative). Serum antibodies against leishmanianegative. Leishmaninin skin test was positive at 72 hours. NNN. cultures positive for Leishmania tropica.
Comment
Cutaneous leishmaniasis (oriental sore), is usually characterized by an indolent ulcer on the face or other exposed parts, three main types being described (Manson-Bahr 1964): a moist early-ulcerative form, a dry late-ulcerative form, and the relapsing lupoid type (leishmaniasis recidiva). This case is unusual because of the florid inflammatory response around the ulcer and involving the cheek and nose, which is not normally a feature of the condition. Dr A Warin: This diffuse inflammatory appearance of cutaneous leishmaniasis is unusual. Out of 142 cases of leishmaniasis that I saw in one year in Shiraz, Iran, only 2 had this clinical appearance. All the others conformed to the typical 'acute oriental sore' or the chronic lupoid leishmaniasis, looking very like lupus vulgaris. In my experience, the use of meglumine antimoniate given intramuscularly daily for 2 to 3 weeks, or given intralesionally, played very little part in speeding up resolution in the acute oriental sore. The same may be said of metronidazole. Intralesional meglumine antimoniate with or without corticosteroids in lupoid leishmaniasis was only marginally effective. Initially some improvement would occur, but usually the granuloma reappeared as before.
Dr W H Jopling: This is a very interesting and unusual case. Instead of a classical lesion of cutaneous leishmaniasis with a histiocyte/macrophage histology and L-D bodies (amastigotes) identifiable in sections, the patient has presented with a lesion which is typical clinically and histologically of leishmaniasis recidiva (lupoid leishmaniasis) yet there is no past history of cutaneous leishmaniasis; in fact, apart from visiting Rumania last year, the patient has never previously been in a country in which the disease is endemic.
As regards treatment, the fact that culture has proved the presence of leishmaniae makes it mandatory to give sodium stibogluconate injections, and I would advise combining this with two or more treatments with Grenz rays at intervals of 3 weeks. Dr A Griffiths: It is often suggested at clinical meetings that it is unnecessary to treat cutaneous leishmaniasis. The patient is a good example of why this attitude is wrong. First, cutaneous leishmaniasis does not always heal in a year; some last eighteen months or two years, some turn into the relapsing or recidivant form, whilst a few may develop disseminated anergic leishmaniasis. Secondly, the scarring caused by the spontaneously healing lesion is frequently very disfiguring. Lastly, those of us who have been to Shiraz and have seen many cases of leishmaniasis will agree that the morbidity of the disease for the year or two of its activity may be considerable. I would treat this patient with adequate pentavalent antimony by daily intravenous doses. However, it is fair to say that there is, so far, no really effective treatment for cutaneous leishmaniasis. A nitrofurfurylidene compound (Nifurtimox) has proved of great interest in the treatment ofChagas' disease, and I know of two encouraging preliminary trials of its use in cutaneous leishmaniasis.
